Charles E. Grimshaw
Charles E. “Ched” Grimshaw earned his BS in chemistry from UC Berkeley and his PhD in biochemistry with W.W. “Mo” Cleland at UW Madison. After post-doctoral studies at Harvard with Jeremy Knowles, he spent 14 years conducting NIH-funded research at The Scripps Research Institute, The Whittier Institute, and finally UCSD, before migrating to industry with Igen (now Meso Scale Discovery) in 1996. At Signal Pharmaceuticals, later acquired by Celgene, Dr. Grimshaw directed drug discovery enzymology and screening, and helped manage several international collaborations. At Syrrx, later acquired by Takeda Pharmaceuticals, Dr. Grimshaw has held positions of increasing responsibility, most recently serving as Director of Enzymology and Biophysical Chemistry at Takeda California. Since 2016, Dr. Grimshaw has worked as an independent Biotech and Pharma consultant with Ched Grimshaw Consulting, LLC. Dr. Grimshaw’s expertise in assay development, mechanistic enzymology, and structure-based drug design covers a broad range of target classes.